The evidence presented in this case report strengthens the argument that CDK4/6 may play an important role in the pathogenesis of CDK4-amplified ARMS and that abemaciclib in combination with temozolomide and irinotecan may abrogate tumor growth and improve outcomes. Here, CDK4 is linked to alveolar rhabdomyosarcoma.